Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.2
4.8
Journals
Nutrients
Special Issues
Probiotics, Prebiotics, Postbiotics and Gut Microbiota in Lung Health and...
nutrients-logo
Submit to Nutrients Review for Nutrients Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Probiotics, Prebiotics, Postbiotics and Gut Microbiota in Lung Health and Disease

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Prebiotics and Probiotics".

Deadline for manuscript submissions: closed (20 December 2022) | Viewed by 5309

Special Issue Editors

Dr. Muriel Thomas

E-Mail Website
Guest Editor
Micalis Institute, Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement UMR1319, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
Interests: nutrition; microbiota; health; gut–lung axis; pro- and prebiotics
Dr. Vinciane Saint-Criq

E-Mail Website
Guest Editor
Micalis Institute, AgroParisTech,INRAE, Université Paris-Saclay,78350 Jouy-en-Josas, France
Interests: lung physiology; ion transport; microbiota; nutrition; inflammation

Special Issue Information

Dear Colleagues,

It has long been known that lung diseases can be associated with gut symptoms or disorders, and in recent years, the gut–lung axis has become a prominent area of interest for research. Recent studies have demonstrated that lung infections affect the gut microbiota equilibrium,  negatively impacting the pulmonary tissue and rendering it more susceptible to secondary infections. Chronic lung diseases, such as asthma or COPD, are also associated with a dysbiotic gut microbiota, and although it is unclear whether restoring gut eubiosis could alleviate lung pathologies, several studies suggest that diet, pro-, pre- and postbiotics could significantly impact chronic lung disease development and progression.

In this Special Issue, original research articles and reviews describing basic, clinical and applied studies on novel and significant advances in all areas relevant to the gut–lung axis are welcome. Topics of interest may include, but are not limited to, the following: nutrition, pro-, pre- and postbiotic effect on acute and chronic lung diseases; relationship between gut commensal strains and lung health/pathologies; and relationship between diet and lung health. We look forward to receiving your contributions.

Dr. Muriel Thomas
Dr. Vinciane Saint-Criq
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pro-, pre- and postbiotics
  • gut-lung axis
  • chronic respiratory diseases
  • gut microbiota
  • lung health
  • lung diseases
  • diet
  • nutrition

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 3489 KiB  
Article
An Isolate of Streptococcus mitis Displayed In Vitro Antimicrobial Activity and Deleterious Effect in a Preclinical Model of Lung Infection
by Elliot Mathieu, Quentin Marquant, Florian Chain, Edwige Bouguyon, Vinciane Saint-Criq, Ronan Le-Goffic, Delphyne Descamps, Philippe Langella, Thomas A. Tompkins, Sylvie Binda and Muriel Thomas
Nutrients 2023, 15(2), 263; https://doi.org/10.3390/nu15020263 - 4 Jan 2023
Cited by 1 | Viewed by 2408
Abstract
Microbiota studies have dramatically increased over these last two decades, and the repertoire of microorganisms with potential health benefits has been considerably enlarged. The development of next generation probiotics from new bacterial candidates is a long-term strategy that may be more efficient and [...] Read more.
Microbiota studies have dramatically increased over these last two decades, and the repertoire of microorganisms with potential health benefits has been considerably enlarged. The development of next generation probiotics from new bacterial candidates is a long-term strategy that may be more efficient and rapid with discriminative in vitro tests. Streptococcus strains have received attention regarding their antimicrobial potential against pathogens of the upper and, more recently, the lower respiratory tracts. Pathogenic bacterial strains, such as non-typable Haemophilus influenzae (NTHi), Pseudomonas aeruginosa (P. aeruginosa) and Staphylococcus aureus (S. aureus), are commonly associated with acute and chronic respiratory diseases, and it could be interesting to fight against pathogens with probiotics. In this study, we show that a Streptococcus mitis (S. mitis) EM-371 strain, isolated from the buccal cavity of a human newborn and previously selected for promising anti-inflammatory effects, displayed in vitro antimicrobial activity against NTHi, P. aeruginosa or S. aureus. However, the anti-pathogenic in vitro activity was not sufficient to predict an efficient protective effect in a preclinical model. Two weeks of treatment with S. mitis EM-371 did not protect against, and even exacerbated, NTHi lung infection. Full article
(This article belongs to the Special Issue Probiotics, Prebiotics, Postbiotics and Gut Microbiota in Lung Health and Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 330 KiB  
Review
Probiotics Administration in Cystic Fibrosis: What Is the Evidence?
by Susanna Esposito, Ilaria Testa, Elena Mariotti Zani, Daniela Cunico, Lisa Torelli, Roberto Grandinetti, Valentina Fainardi, Giovanna Pisi and Nicola Principi
Nutrients 2022, 14(15), 3160; https://doi.org/10.3390/nu14153160 - 30 Jul 2022
Cited by 11 | Viewed by 2340
Abstract
In the last 20 years, gut microbiota in patients with cystic fibrosis (CF) has become an object of interest. It was shown that these patients had gut dysbiosis and this could explain not only the intestinal manifestations of the disease but also part [...] Read more.
In the last 20 years, gut microbiota in patients with cystic fibrosis (CF) has become an object of interest. It was shown that these patients had gut dysbiosis and this could explain not only the intestinal manifestations of the disease but also part of those involving the respiratory tract. The acquisition of previously unknown information about the importance of some bacteria, i.e., those partially or totally disappeared in the gut of CF patients, in the regulation of the activity and function of the gut and the lung was the base to suggest the use of probiotics in CF patients. The main aim of this paper is to discuss the biological basis for probiotic administration to CF patients and which results could be expected. Literature analysis showed that CF intestinal dysbiosis depends on the same genetic mutations that condition the clinical picture of the diseases and is aggravated by a series of therapeutic interventions, such as dietary modifications, the use of antibiotics, and the administration of antacids. All this translates into a significant worsening of the structure and function of organs, including the lung and intestine, already deeply penalized by the genetic alterations of CF. Probiotics can intervene on dysbiosis, reducing the negative effects derived from it. However, the available data cannot be considered sufficient to indicate that these bacteria are essential elements of CF therapy. Further studies that take into account the still unsolved aspects on how to use probiotics are absolutely necessary. Full article
(This article belongs to the Special Issue Probiotics, Prebiotics, Postbiotics and Gut Microbiota in Lung Health and Disease)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop